NCT02986867View on ClinicalTrials.gov

SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

NACompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 13, 2017

Primary Completion Date

March 7, 2018

Study Completion Date

March 7, 2018

Conditions
Urothelial CarcinomaMelanomaCervical Carcinoma in Situ
Interventions
RADIATION

SAbR Treatment of Lesions

"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."

Trial Locations (1)

75063

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02986867 - SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma | Biotech Hunter | Biotech Hunter